| Identification | Back Directory | [Name]
HOE 140 | [CAS]
130308-48-4 | [Synonyms]
S-0765
HOE I40
HOE 140
H0E-140
JE-049)
Icatibant
Icatibant [inn]
HOE 140 USP/EP/BP
HOE 140 2ACOH 4H2O
Icatibatide Acetate
Icatibant
(HOE-140
[DES-ARG10] HOE 140
138614-30-9 (Acetate)
RRP-(HYP)-G-(THI)-S-(D-TIC)-(OIC)-R
D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin
D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic
D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG
D-ARGINYL-[HYP3,THI5,D-TIC7,OIC8]-BRADYKININ
Des-Arg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin
H-D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG-OH
H2N-D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG-OH
D-ARG-ARG-PRO-HYP-GLY-THI-SER-D-TIC-OIC-ARG 2ACOH 4H2O
D-ARGINYL-[HYP3,THI5,D-TIC7,OIC8]-BRADYKININ 2ACOH 4H2O
D-Arg-L-Arg-L-Pro-L-t4Hyp-Gly-L-Thi-L-Ser-D-Tic-L-Oic-L-Arg-OH
D-Arg-L-Arg-L-Pro-L-t4Hyp-Gly-3-(2-Thienyl)-L-Ala-L-Ser-D-Tic-[(3aS,7aS)-L-Oic-]-OH
D-Arg-L-Arg-L-prolyl-L-Hyp-Gly-L-(2-thienyl)Ala-L-Ser-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2α,3β,7aβ)-octahydro-1H-indole-2-carboxylic acid
D-ARGINYL-L-ARGINLYL-L-PROLYL-TRANS-4-HYDROXY-L-PROLYLGLYCYL-3-(2-THIENYL)-L-ALANYL-L-SERYL-D-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBONYL-L-(2ALPHA, 3BETA, 7ABETA)-OCTAHYDRO-1H-INDOLE-2-CARBONYL
L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-
D-ARGINYL-L-ARGINLYL-L-PROLYL-TRANS-4-HYDROXY-L-PROLYLGLYCYL-3-(2-THIENYL)-L-ALANYL-L-SERYL-D-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBONYL-L-(2ALPHA,3BETA,7A-BETA)-OCTAHYDRO-1H-INDOLE-2-CARBONYL-L-ARGININE
L-Arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-
Nw-(((S)-2-(2-((2S,4R)-1-(D-arginyl-L-arginyl-L-prolyl)-4-hydroxypyrrolidine-2-carboxamido)acetamido)-3-(thiophen-2-yl)propanoyl)-L-seryl)-N2-((3aS,7aS)-octahydro-1H-indole-2-carbonyl)-N2-((R)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-arginine | [Molecular Formula]
C59H89N19O13S | [MDL Number]
MFCD00213940 | [MOL File]
130308-48-4.mol | [Molecular Weight]
1304.52 |
| Chemical Properties | Back Directory | [density ]
1.60±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
Water:100.0(Max Conc. mg/mL);76.66(Max Conc. mM) | [form ]
powder
| [pka]
3.60±0.21(Predicted) | [color ]
white
| [Water Solubility ]
Soluble to 1 mg/ml in water | [Sequence]
H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH | [InChIKey]
QASONHYHOCRAHL-DOMVFXHKSA-N | [CAS DataBase Reference]
130308-48-4 |
| Hazard Information | Back Directory | [Description]
Hoe 140 (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin), on bradykinin- and platelet-activating factor (PAF)-induced bronchoconstriction and airway microvascular leakage in anesthetized guinea pigs. Hoe 140 is highly potent and long-acting in inhibiting BK-induced hypotensive responses in the rat. Four hours after s.c. administration of 20nmol kg-1, inhibition still amounted to 60% whereas the effect of 200nmol kg-1 of d-Arg-[Hyp2, Thi5,8, d-Phe7]BK was not significant[1-2].
| [History]
Icatibant, developed by Germany's Jerini AG (which was acquired by Shire in 2008 and subsequently by Takeda), is a specific bradykinin B2 receptor antagonist used to treat acute episodes of hereditary angioedema. It works by inhibiting the effects of bradykinin, which is associated with localized swelling, inflammation, and pain. First approved in the European Union in 2008 under the trade name Firazyr for the treatment of acute HAE attacks in adults, it received accelerated approval from the FDA in 2011 via priority review for acute HAE attacks in patients aged 18 years and older. In 2017, the European Union further expanded its approved indications to include pediatric and adolescent HAE patients aged 2 years and above.
 | [Uses]
Antagonist (bradykinin). | [Definition]
ChEBI: A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acut
attacks of hereditary angioedema in adult patients. | [Brand name]
Metastat (CollaGenex). | [Biological Activity]
A potent and selective bradykinin B2 antagonist. HOE-140 is a useful tool for discrimination of the physiological roles of bradykinin B2 versus B1 receptors. Displays a protective effect in myocardial reperfusion injury. | [storage]
Store at -20°C | [References]
[1] K. Wirth. “Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies.” British Journal of Pharmacology 102 3 (1991): 774–777.
[2] T Sakamoto. “Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig.” European journal of pharmacology 213 3 (1992): 367–73.
|
|
|